Rett syndrome
The company is prepping a study of its Alzheimer's risk test CogniMir, with the aim of making it available for pharma research in late 2023 or early 2024.
DiamiR Biosciences, JADBio Partner on Machine Learning for Assay Development
Under the agreement, DiamiR will use JADBio's Automated Machine Learning Platform to validate its Alzheimer's and Rett syndrome panels.
DiamiR Wins $3.9M in NIH Funding for Neurological Disease Diagnostic Development
The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome.